A novel cell lysis solution with advantageous use characteristics for rAAV manufacturing that can lead to greater downstream recovery by minimizing upstream loss
Many gene therapies and viral vaccines rely on a high dose of recombinant adeno-associated virus (rAAV) to deliver therapeutic DNA to patient cells, which may be challenging. Improving titer during the upstream process is important but recovering the titer during the harvest process is critical. Recovery of assembled rAAV particles can be challenging as their cytoplasmic localization requires release through cell lysis and separation from resulting cellular debris. Chemical lysis is the industry favored method of lysis to retrieve rAAV due to its scalability as well as other factors; however, variable recovery and need for environmental regulatory compliance has led to continuous development and testing of chemical solutions. In this presentation, we will demonstrate the benefits of using a novel cell lysis solution which can rapidly rupture cell membranes across a wide range of operating conditions, is compatible with traditional DNA removal agents and also provides preferential yield and titer of rAAV. The features of this cell lysis agent, along with ease-of-use qualities such as relatively low viscosity and room temperature stability at storage conditions, make it the optimal solution to improve the overall viral vector manufacturing process by providing robust and efficient cell lysis that may allow for high titer rAAV recovery.
This presentation was given at BPI Europe, April 12, 2024.
Presented by:
 |
Joe Gallagher |